Investor Presentaiton
Investor presentation
Full year 2018
Sales per key product for Q4 2018 and full year 2018
Slide 107
Reported currencies
TresibaⓇ
Sales Q4 2018 (mDKK)
Sales split Sales full year 2018 (mDKK)
Sales split
2,172
7%
8,035
7%
LevemirⓇ
2,832
10%
11,195
10%
FiaspⓇ
206
1%
590
1%
NovoRapidⓇ
NovoMix®
VictozaⓇ
4,824
16%
18,763
17%
2,239
8%
9,480
8%
6,500
22%
24,333
22%
OzempicⓇ
992
3%
1,796
2%
SaxendaⓇ
1,229
4%
3,869
3%
Diabetes care and obesity¹
24,897
84%
93,904
84%
NovoSevenⓇ
1,956
7%
7,881
7%
NovoEight®
396
1%
1,354
1%
NorditropinⓇ
1,962
7%
6,834
6%
Biopharmaceuticals¹
4,835
16%
17,927
16%
Total¹
29,732
100%
111,831
100%
1 Values are higher than the sum of the total elements listed due to residual values from products not listedView entire presentation